title: Improved regeneration and de novo bone formation in a diabetic zebrafish model treated with paricalcitol and cinacalcet.
abstract: Bone changes related to diabetes have been well stablished, but few strategies have been developed to prevent this growing health problem. In our work, we propose to investigate the effects of calcitriol as well as of a vitamin D analog (paricalcitol) and a calcimimetic (cinacalcet), in fin regeneration and de novo mineralization in a zebrafish model of diabetes. Following exposure of diabetic transgenic Tg(ins:nfsb-mCherry) zebrafish to calcitriol, paricalcitol and cinacalcet, caudal fins were amputated to assess their effects on tissue regeneration. Caudal fin mineralized and regenerated areas were quantified by in vivo alizarin red staining. Quantitative real-time PCR was performed using RNA from the vertebral column. Diabetic fish treated with cinacalcet and paricalcitol presented increased regenerated and mineralized areas when compared with non-treated diabetic group, while no significant increase was observed in non-diabetic fish treated with both drugs. Gene expression analysis showed an up-regulation for runt-related transcription factor 2b (runx2b), bone gamma-carboxyglutamic acid-containing protein (bglap), insulin a (insa) and insulin b (insb) and a trend of increase for sp7 transcription factor (sp7) in diabetic groups treated with cinacalcet and paricalcitol. Expression of insra and vdra was up-regulated in both diabetic and nondiabetic fish treated with cinacalcet. In nondiabetic fish treated with paricalcitol and cinacalcet a similar increase in gene expression could be observed but not so pronounced. The increased mineralization and regeneration in diabetic zebrafish treated with cinacalcet and paricalcitol can be explained by increased osteoblastic differentiation and increased insulin expression indicating pro-osteogenic potential of both drugs.
authors.affiliation: Center of Marine Sciences (CCMAR), Faro, Portugal.|PhD Program in Biomedical Sciences, University of Algarve, Faro, Portugal.
authors.forename: Filipe R
authors.initials: FR
authors.lastname: Carvalho
authors.affiliation: Department of Biomedical Sciences and Medicine, University of Algarve, Faro, Portugal.
authors.forename: Ana R
authors.initials: AR
authors.lastname: Fernandes
authors.affiliation: Center of Marine Sciences (CCMAR), Faro, Portugal.|Department of Biomedical Sciences and Medicine, University of Algarve, Faro, Portugal.
authors.forename: M Leonor
authors.initials: ML
authors.lastname: Cancela
authors.affiliation: Center of Marine Sciences (CCMAR), Faro, Portugal.|Department of Biomedical Sciences and Medicine, University of Algarve, Faro, Portugal.
authors.forename: Paulo J
authors.initials: PJ
authors.lastname: Gavaia
mesh_terms: D000671:Amputation, Surgical; D058500:Animal Fins / Q000187:drug effects* / Q000293:injuries / Q000502:physiology; D000818:Animals; D057966:Calcimimetic Agents / Q000494:pharmacology*; D002454:Cell Differentiation / Q000187:drug effects; D000069449:Cinacalcet / Q000494:pharmacology*; D003921:Diabetes Mellitus, Experimental; D004195:Disease Models, Animal; D004872:Ergocalciferols / Q000494:pharmacology*; D007150:Immunohistochemistry; D010006:Osteoblasts / Q000187:drug effects* / Q000378:metabolism; D010012:Osteogenesis / Q000187:drug effects* / Q000502:physiology; D060888:Real-Time Polymerase Chain Reaction; D012038:Regeneration / Q000187:drug effects* / Q000502:physiology; D015027:Zebrafish
chemical_list: D057966:Calcimimetic Agents; D004872:Ergocalciferols; C084656:paricalcitol; D000069449:Cinacalcet